Breast cancer cells were chosen on the basis of their estrogen (ER), progesterone (PR), and ERBB2 (HER2) receptor assets, in order to simulate a differential response to RT between triple negative breast and luminal adenocarcinomas. This evidence concerns the gene ERBB2 and breast carcinoma.